In patients with allergic rhinitis, intranasal corticosteroids lead to a significantly lower mean Total Nasal Symptom Score when compared to oral antihistamines.

This study aimed to compare the mean Total Nasal Symptom Score (TNSS) between the use of intranasal corticosteroids and oral antihistamines in the management of allergic rhinitis (AR).

In this randomized controlled trial, 100 AR-affected participants (aged 20-60 years) were equally divided into Groups A and B. Group A received intranasal corticosteroids (Fluticasone furoate nasal spray at 110 μg daily), while Group B received oral antihistamine (Fexofenadine 120 mg once a day). After four weeks, TNSS was assessed with a potential range of 0 (no symptoms) to 12 (very severe symptoms).

Demographic variables and TNSS were examined utilizing descriptive statistics. An independent sample t-test compared scores between groups, and a paired sample t-test assessed changes within groups before and after the 4-week therapy. The study's results underwent analysis post-treatment.

The mean TNSS scores in intranasal corticosteroids and oral antihistamines groups are depicted in Table 1:

The application of intranasal corticosteroids led to a substantially lower mean TNSS when compared to oral antihistamines. This suggests that, intranasal corticosteroids are a relatively effective regimen for AR management.